and FSH is not impaired, demonstrating that the pituitary can synthesize gonadotrophin hormones and in response to LH/FSH-RH release them into the blood. A large proportion of these patients with post-pill amenorrhoea will ovulate if treated with clomiphene or pituitary gonadotrophin. Fig 8 shows the findings in a patient with galactorrhcea while taking cestrogen-progestogen oral contraception. The pituitary secretion of LH was almost completely suppressed and, following discontinuation of oestrogen-progestogen oral contraception and the substitution of a progestogenonly preparation, the LH level rapidly returned to normal; the galactorrhcea also disappeared when the combined preparation was stopped.
Animal studies by Frith & Hooper (1971) have indicated that the hypothalamus contains enzymes which affect the turnover of polypeptides, oxytocin and gonadotrophin releasing hormone. Ovulation inhibitors stimulate an increase of this enzyme activity in the hypothalamus and inhibit gonadotrophin release, most likely by controlling the availability of gonadotrophin releasing hormone. The balance ofevidence suggests, therefore, that a central site of action at the hypothalamus is responsible for post-pill amenorrhoea rather than an effect on the pituitary or ovary. This appears to be due to the effect on the hypothalamus of synthetic sex hormones, particularly oestrogen. Reports on the long-term follow-up of women taking oral contraceptives have implied that ovulation following discontinuation of these agents is usually associated with a history of irregular menses prior to the use of oral contraceptives. Instances do, however, occur where women who have had a perfectly regularmenstrual cycle previously develop amenorrhcea following even short periods of oral contraception. It is doubtful, therefore, if the over-suppression syndrome is doseor time-related. In patients who do not respond to treatment with clomiphene alone, we are at present studying the effect of clomiphene and releasing hormone and we have successfully induced ovulation with this combination. There is much experimental evidence to substantiate the view that gonadotrophic secretion and hence reproductive function are dependent on central nervous stimuli and the steroid environment of both the brain and the anterior pituitary gland (Harris 1972).
Central nervous stimuli related to reproductive function are mediated by hypothalamic factors (releasing hormones) which are transported by hypophyseal portal vessels to the anterior pituitary gland. One such factor -gonadotrophin releasing hormonehas been extracted from hypothalamic tissue and characterized. It is potent, as is its synthetic form (LH/FSH-RH), in the release of both LH and FSH from the anterior pituitary and can therefore be used as a test of pituitary function (Schally et al. 1971) . A potential use of LH/FSH-RH lies in the treatment of anovulatory sterility (Akande et al. 1972 , Newton & Collins 1972 . However, for ovulation to be achieved following its administration two conditions require to be fulfilled. First, the anterior pituitary must be capable of a vigorous gonadotrophic response to a preliminary test dose of LH/FSH-RH (Keller 1972) . Secondly, the ovaries should contain ripe follicles; this state can be assessed by measuring plasma cestrogen levels which are normally raised prior to the preovulatory surge of gonadotrophins .
LH/FSH-RH may also be useful in the treatment of certain dysfunctions of spermatogenesis. Furthermore, when analogues of the releasing hormone become available they may provide easier and safer methods of long-term contraception than are now possible. 
Amenorrhbea and Galactorrhwea
Among the various causes of amenorrheea and galactorrheea, the contraceptive pill is one of the most important. Table 1 compares the findings in a recent series reported by Shearman & Smith (1972) and those in 14 cases recently seen in the Chelsea Hospital for Women. In each series the absence of the very common emotional causes of hypothalamic suppression suggests that these are less likely to promote galactorrhcea than other causes more profoundly affecting hypothalamic activity. When an apparent clear-cut cause for galactorrhoea is present, however, such as oral contraceptives, it must never be assumed that there is not some other possible cause present, notably a pituitary tumour. Several cases are on record in which a pituitary tumour was present as well as some other precipitating cause, such as pregnancy or the pill (Young et al. 1967 , Macleod et al. 1970 , Hughes et al. 1972 ). Galactorrhoea is not invariably associated with secondary amenorrhcea, as was the case in 3 patients recently seen at the Chelsea Hospital for Women; one of these has recently become pregnant without treatment. If the patient is anxious for a pregnancy, treatment to stimulate ovulation with clomiphene and/ or human gonadotrophin has a chance of success which is comparable with that achieved in our patients with post-pill amenorrheea without galactorrhcea who had a pregnancy rate of 40%. If a pregnancy is not desired, there is a possibility of spontaneous cure, as happened in one of our own patients. If galactorrhcea is really troublesome, success has been reported with L-Dopa, 0.5 g given six-hourly with cessation of galactorr-hcEa in 11 of 14 patients (Turkington 1972) . Of particular interest is the report of successful treatment of galactorrhoea with the ergot alkaloid, bromergocryptine (Lutterbeck et al. 1971 , Besser et al. 1972 ). This drug given in doses varying between 3 and 9 mg/day was successful in suppressing galactorrhcea and allowing resumption of menstruation.
